STE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q4

FY2027Q1

1.48B

+8.07%

2.530

+9.05%

1.60B

+7.81%

2.875

+4.93%

1.49B

+6.86%

2.535

+8.33%

Estimates Revision

The market is revising Upward the revenue expectations for STERIS plc (STE) for FY2026, with the revenue forecasts being adjusted by 0.11% over the past three months. During the same period, the stock price has changed by 2.45%.

Revenue Estimates for FY2026

Revise Upward

+0.11%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+1%

In Past 3 Month

Stock Price

Go Up

+2.45%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast STE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STE is 289.33 USD with a low forecast of 285.00 USD and a high forecast of 295.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 254.070

Low

285.00

Averages

289.33

High

295.00

Current: 254.070

Low

285.00

Averages

289.33

High

295.00

JPMorgan

Neutral

maintain

2025-12-05

Reason

JPMorgan

Price Target

2025-12-05

maintain

Neutral

Reason

JPMorgan raised the firm's price target on Stora Enso to EUR 10.50 from EUR 9.20 and keeps a Neutral rating on the shares.

KeyBanc

Brett Fishbin

Overweight

maintain

$277 -> $288

2025-07-22

Reason

KeyBanc

Brett Fishbin

Price Target

$277 -> $288

2025-07-22

maintain

Overweight

Reason

KeyBanc analyst Brett Fishbin raised the firm's price target on Steris to $288 from $277 and keeps an Overweight rating on the shares. The firm notes that underlying MedTech trends appear positive heading into Q2 earnings season, and KeyBanc believes sub-sector underperformance this year has been more attributable to macro uncertainties such as the impact of tariffs. Specifically, the firm's Key First Look Data has indicated a high-single digit volume growth in the hospital category through Q2. KeyBanc continues to view tariffs as the biggest overhang to the group, but consensus estimates at least now incorporate the known base-case impacts.

Morgan Stanley

Equal Weight -> Overweight

upgrade

$260 -> $276

2025-07-15

Reason

Morgan Stanley

Price Target

$260 -> $276

2025-07-15

upgrade

Equal Weight -> Overweight

Reason

Morgan Stanley upgraded Steris to Overweight from Equal Weight with a price target of $276, up from $260. The firm's work on the potential margin gains from the shift to E-Beam, consolidation of volumes and pricing power on NESHAP compliance costs, improving bioprocessing trends, and potential tailwind from Olympus' import ban into the U.S., all leave the firm more positive on Steris, the analyst tells investors in a research note.

Jefferies

David Windley

Hold

initiated

$263

2025-05-29

Reason

Jefferies

David Windley

Price Target

$263

2025-05-29

initiated

Hold

Reason

Citizens JMP

Outperform

maintain

$265 -> $280

2025-05-16

Reason

Citizens JMP

Price Target

$265 -> $280

2025-05-16

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Steris to $280 from $265 and keeps an Outperform rating on the shares. Steris ended fiscal 2025 with a strong quarter that included a marginal beat on the top line and 5% bottom-line upside, the analyst tells investors in a research note. The company has built an impressive track record of consistent execution and the portfolio remains largely non-elective in nature, and fiscal 2026 should be another solid year for the company and the stock, Citizens says.

JMP Securities

David Turkaly

Buy

Reiterates

$265

2025-04-10

Reason

JMP Securities

David Turkaly

Price Target

$265

2025-04-10

Reiterates

Buy

Reason

Valuation Metrics

The current forward P/E ratio for STERIS plc (STE.N) is 23.89, compared to its 5-year average forward P/E of 24.56. For a more detailed relative valuation and DCF analysis to assess STERIS plc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

24.56

Current PE

23.89

Overvalued PE

27.03

Undervalued PE

22.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

16.71

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

18.50

Undervalued EV/EBITDA

14.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.08

Current PS

0.00

Overvalued PS

4.50

Undervalued PS

3.65

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 17029.8% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 17029.8% over the last month.

Sold

Bought

STE News & Events

Events Timeline

No data

News

3.0

12-09Barron's

Bullish Charts Highlight These Healthcare Stocks: GE Healthcare, STERIS, and Hinge Health

3.0

12-04CNBC

A lesser-known medical device stock shows potential for a 20% increase, based on chart analysis.

3.0

12-01CNBC

Medical Device Stocks Exhibit 'Cup-and-Handle' Chart Pattern: Implications for the Sector

People Also Watch

Frequently Asked Questions

What is STERIS plc (STE) stock price today?

The current price of STE is 254.07 USD — it has increased 0.91 % in the last trading day.

What is STERIS plc (STE)'s business?

STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device research and manufacturing facilities, in particular those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.

What is the price predicton of STE Stock?

What is STERIS plc (STE)'s revenue for the last quarter?

STERIS plc revenue for the last quarter amounts to 1.46B USD, increased 9.89 % YoY.

What is STERIS plc (STE)'s earnings per share (EPS) for the last quarter?

STERIS plc. EPS for the last quarter amounts to 1.95 USD, increased 29.14 % YoY.

What changes have occurred in the market's expectations for STERIS plc (STE)'s fundamentals?

How many employees does STERIS plc (STE). have?

STERIS plc (STE) has 17787 emplpoyees as of December 16 2025.

What is STERIS plc (STE) market cap?

Today STE has the market capitalization of 24.94B USD.